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Abstract Bisheteroarylpiperazines (BHAPs) are highly specific 
inhibitors of human immunodeficiency virus type 1 (HIV-1) re- 
verse transcriptase (RT). BHAP-resistant HIV-1 is sensitized to 
other classes of nonnucleoside RT inhibitors and this has been 
primarily attributed to a proline-to-leucine substitution at amino 
acid 236 (P236L) of HIV-1 RT. To understand the basis for the 
in vitro sensitization-resistance phenomenon, single base pair mu- 
tations at amino acid P236 in HIV-1 RT were introduced to 
obtain P236L, P236T, P236H, P236R, and P236A HIV-1 RT 
mutants. Active HIV-I RT mutants H235W, D237T, and 
H235WlD237T/T240K, containing substitutions from HIV-2 
RT, were also cloned, expressed, and purified. Three BHAPs 
(U-88204E, U-87201E, and U-90125S) and the pyridinone L- 
697,661 were selected to quantitatively assess the effects of these 
amino acid substitutions on sensitization to L-697,661 and resis- 
tance to the BHAPs. The HIV-1 RT mutants bearing single 
(H235W; D237T) or multiple (H235WID237T/T240K) HIV-2 
RT substitutions around the conserved P236 conferred little resis- 
tance or sensitization to these RT inhibitors. The inhibition pro- 
files of the P236 HIV-1 RT mutants demonstrated a direct corre- 
lation between sensitization to L-697,661 and resistance to the 
BHAPs. These results suggest alterations in the shape of the 
binding pocket as the mechanism by which the P236L mutation 
confers resistance to the BHAPs and sensitization to L-697,661. 
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I. Introduction 
Human immunodeficiency virus type 1 (HIV-I) reverse tran- 
scriptase is a well known target for chemotherapeutic interven- 
tion of AIDS. Recently, several classes of nonnucleoside re- 
verse transcriptase inhibitors (NNRTIs), which are also potent 
inhibitors of HIV-1 replication in cell culture, have been identi- 
fied. These include the pyridinone L-697,661 [1], nevirapine 
[2,3], the TIBO derivatives [4], TSAO [5], HEPT [6], ino- 
phyllums [7], and the BHAPs [8,9]. Despite their structural 
dissimilarity, they are all relatively inactive against HIV-2 RT 
and, in general, are non-competitive with respect o substrates. 
The three-dimensional structure of HIV-1 RT complexed 
with nevirapine revealed that it binds to the enzyme in a hydro- 
phobic pocket which is close to the polymerase active site of the 
p66 subunit [10]. This is consistent with the earlier affinity 
labeling [11,12] and mutational studies [12,13] which implicated 
interaction of nevirapine with the tyrosines, at positions 181 
and 188 of HIV-1 RT. Moreover, HIV-1 RT enzymes mutated 
at either of these positions, with the corresponding amino acids 
from HIV-2 RT, show high resistance to TIBO R82150, L- 
697,661, and nevirapine [14]. When HIV-1 was grown in the 
presence of L-697,661, viral variants were resistant o all these 
three classes of nonnucleosides [15]. These [14,15] and other 
studies [1,7,16-21] suggest that most classes of NNRTIs  appear 
to share the same binding pocket on the enzyme [10]. 
Recently, a BHAP (U-90152S)-resistant H IV-1 was found to 
contain a proline to leucine mutation at 236 (P236L) of HIV-1 
RT that conferred increased sensitivity to L-697,661 [22]. How 
the P236L mutation in HIV-1 RT triggers both resistance to 
U-90152S and sensitization to L-697,661, is not known. To 
address this question, we constructed point mutants by site- 
directed mutagenesis at and around P236 of HIV-I RT and 
studied their inhibition profiles in the presence of these 
NNRTIs.  Our results suggest alteration in the shape of the 
binding pocket as the mechanism for the P236L-mediated resis- 
tance to the BHAPs and sensitization to L-697,661. 
*Corresponding author. Fax: (1) (616) 385 5488. 
Abbreviations." HIV-1, HIV-2, human immunodeficiency virus types 1 
and 2; RT, reverse transcriptase; AIDS, acquired immunodeficiency 
syndrome; IMAC, immobilized metal affinity chromatography; SDS, 
sodium dodecyl sulfate; BSA, bovine serum albumin; TCA, trichlo- 
roacetic acid; TIBO R82150, (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3- 
methyl-2-butenyl)imidazo[4,5,1-j,k][ 1 4 -benzodiazepin-2(l H)- thione; 
TSAO, [2',5"-bis-O(tert-butyl-dimethylsilyl)]-3"-spiro-5"-(4-amino-l", 
2"-oxathiole-2",2"-dioxide); HEPT, 1-[(2-hydroxyethoxy)-methyl]-6- 
(phenylthio) thymine; BHAP, bisheteroarylpiperazine; NNRTIs, non- 
nucleoside reverse transcriptase inhibitors; DMSO, dimethylsulfoxide; 
PCR, polymerase chain reaction, IPTG, isopropyl-fl-D-thiogalactopyr- 
anoside. 
2. Materials and methods 
2.1. HIV-1 RT inhibitors and other chemicals 
L-697,661, U-88204E, U-87201E, and U-90152S were kindly sup- 
plied by Drs. J.R. Palmer, D.L. Romero and H.W. Smith of Upjohn 
Laboratories. General laboratory chemicals were obtained from Sigma. 
Protein reagents, SDS, Tris, ammonium persulfate, acrylamide and 
bis-acrylamide were purchased from Bio-Rad. Molecular weight mark- 
ers, low melting point agarose, Taq polymerase, T4 ligase, restriction 
enzymes EcoRI and HindIII were from GIBCO/BRL. Glass microfiber 
filter paper was from Whatman. Poly(rA):oligo(dT), deoxythymidine 
and Chelating Sepharose were obtained from Pharmacia/LKB iotech- 
nology Inc. The radiolabled [3H]dTTP was purchased from DuPont 
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NEN and was diluted with unlabeled TTP to a specific activity of 200 
cpm/pmol. The Ultima Gold scintillation fluid was from Packard. Sam- 
ples were counted on a Packard 1900TR liquid scintillation counter 
using 4 ml Omni-vials (Wheaton). Sequencing rade [35S]dATP was 
purchased from Dupont NEN and Sequenase Version 2.0 sequencing 
kit was obtained from USB. Oligonucleotide primers were purchased 
l¥om Genosys Biotechnologies Inc. 
2.2. Site tfirected mutagenesis and expression of H1V-1 RT mutants 
Site-specific point mutations were generated by the 'megaprimer' 
method [23] using the hexa-His tagged HIV-I RT expression clone 
DE-5,2 as the starting material [24]. A list of synthetic oligonucleotide 
primers used to construct mutated RT genes is shown below. 
Designation of primers Sequence (5' 3') 
Upst ream RT 



















The megaprimer method utilizes three oligonucleotide primers and 
two rounds of PCR on the DE-5,2 plasmid DNA coding for HIV-I RT. 
The desired mutation is introduced into the middle of a synthetic ol- 
igonucleotide matching the HIV-1 RT gene at both 3' and 5' to the 
desired mutation. This oligonucleotide is then used as one of the two 
primers in a PCR amplification reaction. The "flanking" primer used 
contains the sequence in the junction between the 5" region of the HIV-I 
RT gene and the prokaryotic expression plasmid pKK223 3 and an 
EcoRl site. Twenty cycles of PCR were performed, and the appropri- 
ately amplified RT gene fragment was purified on a low melting agarose 
gel. In a second PCR, the purified DNA fragment was used as a 
megaprimer, together with a 'flanking' primer which contained se- 
quences in 3' end of the RT gene and a HindII1 site. The amplified 
HIV-I RT gene segment was cleaved with both EcoRI and HindIII. The 
1.7 kb RT gene fragment obtained was subcloned into expression vector 
pKK223 3 that had been digested with EcoRI and HindllI at the 
multiple cloning site [24]. Competent E. coli strain JM 109 was trans- 
formed with the mutated RT construct and selected for ampicillin 
resistance. Resulting colonies were screened for expression of the p66 
HIV-I RT protein upon induction with 1 mM IPTG at 0.40D6{,, nm 
as described elsewhere [24]. The E. coli cells were pelleted, lysed by SDS, 
and the cell lysate was analyzed by 12% SDS-PAGE. The mutated 
region of the selected clones was then sequenced by the dideoxy method 
using Sequenase Version 2.0 sequencing kit and 35S. 
2.3. Purification and characterization of HIV-1 RT mutants 
The crude E. coli extract was prepared by processing 10 g of cell paste 
[25] and adjusting the pH to 8.0 with 2 M Tris-HC1. The IMAC purifi- 
cation of the desired mutants containing the hexa-histidine tag was 
carried out on Ni 2÷ charged columns equilibrated with 20 mM Tris, 0.5 
M NaCI, pH 8.0, containing 10/~g/ml bestatin, leupeptin, aprotinin, 
and 1 mM phenylmethylsulfonyl fluoride and benzamidine. After load- 
ing, the column (8 ml bed volume) was washed with 10 column volumes 
of buffer containing 20 mM Tris, 1 M NaC1, pH 8.0, followed by 10 
column volumes of the same buffer containing 0.5 M NaCI. The unde- 
sirable, bound proteins were washed away with buffer containing 75 
mM imidazole. The HIV-I RT mutants were eluted in the same buffer 
containing 300 mM imidazole. One ml fractions were collected and 
monitored for absorbance at 280 nm. Fractions containing protein, 
after analysis by a 12% SDS-polyacrylamide g l [26], were pooled and 
dialyzed into 200 mM Tris, 1 M NaCl, pH 7.4, and stored at -80°(?. 
2.4. RNA-dependent DNA polymerase RT activity assay 
Reverse transcriptase activity of H1V-1 RT and its mutants was 
determined based on a standard method [24,25,27]. The assay solution 
(50pl) contained poly(rA) : oligo(dT) at a final concentration of 7.5/~M 
based on deca(dT) and 75/IM [3H]dTTP in a buffer containing 25 mM 
Tris, pH 8.5, 5 mM MgCI~, 1.5% glycerol, 50/,tg/ml BSA and 0.01% 
NP-40. l0 ,ul of the RT enzyme or its mutants (4-6 nM) was incubated 
with the assay solution for 10 min at 370C. The specific HIV-1 RT 
activity (units/mg) was determined as described elsewhere [25]. 
2.5. lQso determinations 
For inhibition studies, enzymatic assays were carried out in the pres- 
ence and absence of HIV-1 RT inhibitors. All the inhibitors were pre- 
pared in 50% DMSO as 25 x stock solutions and 2~tl of each inhibitor 
was added to give the desired inhibitor concentration. The final DMSO 
concentration was maintained at <5% in the assay mixture. All assays 
were pertbrmed in triplicate and the concentration of inhibitors that 
produced 50% inhibition (ICs0) were mean values from three independ- 
ent assays. For determination of relative IC50 values with standard 
deviations, statistical analysis of the upper and lower confidence limits 
were calculated using the 3 parameter logistic model [28]. The ICs0 
values were used as a measure of the relative binding affinities of these 
inhibitors versus the HIV-I RT mutants. 
3. Results and discussion 
3.1. Rationale Jor selection of  235, 237, and240 HIV-1 RT  
mutants 
Recent ly  we reported a BHAP(U-90152S) - res i s tance  muta -  
t ion (P236L) in HIV- I  RT  that  confers  increased sensit iv ity to 
the pyr id inone L-697,661 [22]. Ne i ther  o f  these compounds  
inhibit  RNA-dependent  DNA po lymerase  activity o f  HIV-2 
RT. It was noted f rom a compar i son  o f  reverse t ranscr iptase 
amino  acid sequences f rom HIV-1 and  HIV-2 that  P236 is 
conserved while amino  acids at 235, 237, and  240 are non-  
conserved,  as shown below. 
HIV- I  RT  225-PPFLWMGYELHPDKWT-240 
HIV-2 RT  PPFQWMGYELWPTKWK 
This  compar i son  suggested that  if the non-conserved  amino  
acids sur round ing  the conserved prol ine are directly involved 
in b ind ing  to the BHAP U-90152S,  then chang ing  these res idues 
to the cor respond ing  amino  acids f rom HIV-2 RT  shou ld  result  
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Fig. 1. Chemical structures of the BHAPs (a) and L-697,661 (b). Sub- 
stituents lbr the BHAPs are as follows: for U-88204, R = H and 
R" - NH-CH(CH3)2; for U-87201, R = OCH3and R' = NH-CH2-CH3; 
for U-90152, R = NH-SO2-CH 3 and R' = NH-CH(CH3)2. These struc- 
tures were published in the following references: L-697,661 in [14]; 
U-88204E and U-87201E in [8]; U-90152S in [9]. 
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Fig. 2. A 12% SDS-polyacrylamide g lelectrophoresis of IMAC puri- 
fied HIV-1 RT mutants. 
cloned, expressed, and purified a number of HIV-1 RT mu- 
tants: H235W; D237T; and H235W/D237T/T240K. In order to 
facilitate rapid isolation, we engineered these mutants with an 
hexa histidine-containing affinity tag that confers specificity for 
their purification by IMAC. 
3.2. Inhibition studies o f  H1V-1 RT  235, 237, and 240 mutants 
The p66 homodimers of HIV-1 RT are convenient to obtain 
and are useful for rapid in vitro evaluation of HIV-1 RT inhib- 
itors [22,25]. The specific RNA-dependent DNA polymerase 
activity of the wild type p66 homodimer is similar to the specific 
activity of the p661p51 heterodimer [25]. Moreover, incubation 
of the p66 homodimer of the P236L mutant with HIV-1 pro- 
tease produced a stable heterodimeric RT (p661p51). The heter- 
odimer was indistinguishable from the P236L homodimer [22] 
with regard to resistance to U-90152S and sensitization to L- 
697,661 (data not shown). In the present work, therefore, all the 
mutant enzymes were purified as p66 homodimers in a single 
step from crude E. coli extracts, as described for the wild type 
HIV-1 RT [22,24,25]. As controls, three other mutants bearing 
single (H235L; D237N) and double (H235L/D237G) substitu- 
tions unrelated to HIV-2 RT were also obtained (data not 
shown). 
Fig. 1 shows structures of the BHAPs and the L-697,661 used 
for evaluation of their inhibitory potential versus all the 
Table l 
In vitro inhibition of recombinant HIV-l RT mutants by U-90152S and 
L-697,661 
HIV-I RT IC~o (,uM) ~' 
U-90152S L-697,661 
Wild type 0.30 + 0.01 0.23 + 0.01 
H235W 0.10 + 0.003 0.10 _+ 0.003 
D237T 0.31 _+ 0.01 0.15 _+ 0.005 
H235W/D237T/T240K 0.20 _+ 0.006 0.65 _+ 0.02 
~' Data represent mean + S.D. (n = 3). 
mutants of HIV-1 RT. Table 1 shows a comparison of the 
inhibition of HIV-I RT mutants, bearing single and multiple 
mutations derived from HIV-2 RT, with the wild type enzyme. 
These mutant enzymes were found to be essentially indistin- 
guishable from the wild type enzyme in terms of their inhibition 
by U- 90152S and L-697,661. Thus, HIV-1 RT can accommo- 
date these H1V-2 RT amino acids without becoming resistant 
to these drugs. Similar results were obtained with the control 
mutants (H235L; D237N; H235L/D237G) containing substitu- 
tions which were not derived from HIV-2 RT (data not shown). 
These results suggested that the conserved proline at 236 and 
the surrounding residues are unlikely to be involved in direct 
interaction with U-90152S or L-697,661. 
3.3. Inhibition studies with HIV-1 RT  mutants bearing single 
base mutations at 236 
The above studies led us to consider the possibility of P236L- 
mediated alterations in the shape of the binding pocket as the 
mechanism for the observed rug resistance-sensitization phe- 
nomenon. If this hypothesis is correct, then changes at P236 
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Fig. 3. Comparison of relative resistance and sensitization of P236 
HIV-I RT mutants to U-90152S and L-697,661, respectively. Relative 
resistance was calculated as fold-increase in ICs0, by dividing the ICs~ 
for each mutant with the ICs0 for the wild type enzyme. Relative sensi- 
tization was calculated as fold-decrease in ICs0, by dividing the IC~o of 
the wild type enzyme with the ICs0 of the P236 mutant. The data are 
presented relative to the wild type HIV-I RT, which is arbitrarily 
assigned a value of 1. The variation in the triplicate xperiments was 
-<3%. For other details see section 2. 
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Fig. 4. Resistance profiles of P236 HIV-I RT mutants in the presence 
of the BHAPs U-88204E and U-87201E. Other details are the same as 
in Fig. 3. 
monitored in terms of resistance to U-90152S and sensitization 
to L-697,661. In order to test this possibility, site-specific muta- 
tions requiring a single base pair substitution at P236 were 
targeted. Specifically, five HIV-1 RT mutants (P236L, P236T, 
P236H, P236R, P236A) were cloned and expressed in E. coli. 
Fig. 2 shows a SDS-PAGE of the IMAC-purif ied P236 HIV-1 
RT mutants. The specific RNA-dependent DNA polymerase 
activities of these IMAC-purif ied HIV-1 RT mutants is shown 
in Table 2. These mutant enzymes had relative specific activities 
comparable to the wild type HIV-1 RT, indicating that these 
mutations had not affected the functional characteristics of 
these enzymes. 
We have shown previously that the P236L-mediated resis- 
tance to U-90152S and sensitization to L-697,661 can be quan- 
titatively assessed in terms of increase and decrease in IC~,, 
respectively [22]. The ICs0 of each inhibitor was determined 
against each mutant enzyme and compared with the wild type 
H1V-I RT containing P236. The increase in ICs0 (resistance) or 
decrease in ICs0 (sensitization), relative to the wild type HIV-I 
RT, was calculated in terms of fold differences. Fig. 3 shows 
a direct comparison of U-90152S with L-697,661. In contrast 
to the observed resistance to U-90152S, all the P236 mutants 
showed sensitization to L-697,661 (Fig. 3). The largest increase 
in sensitization to L-697,661 was observed with the P236L 
mutant. These results show that the magnitude of resistance to 
U-90152S and sensitization to L-697,661 depends upon the 
substitution at P236. If the relative resistance of a mutant RT 
towards U-90152S is the lowest, the relative sensitization of that 
mutant to L-697,661 is also the lowest (Fig. 3). This direct 
correlation between sensitization to L-697,661 and resistance 
to U-90152S supports the previous evidence [20,21] that these 
structurally dissimilar RT inhibitors share the same binding 
pocket [10]. 
It is interesting to note (Fig. 3) the nature of the amino acids 
substituted for the proline in the HIV-1 RT mutants and their 
effect on resistance/sensitization. At the extreme of the resis- 
tance profile are amino acids with lipophilic sidechains; Leu, 
Ala, and the parent Pro. Intermediate l vels of resistance are 
associated with the more polar amino acids Thr, His, and Arg. 
The observed resistance trend (Fig. 3) does not correlate well 
with the polarity or size of the amino acids present at position 
236 of HIV-1 RT. This suggests that binding of the BHAP 
U-90152S does not involve a specific interaction between the 
drug and the sidechain of the 236 residue of HIV-1 RT. Rather, 
these studies led us to conclude that substitution of alternative 
amino acids for the proline found at the ,813-,814 reverse turn 
[29] of HIV-1 RT alters the geometry of the inhibitor-binding 
pocket. The net result is that the relative binding affinity of the 
enzyme's altered pocket is increased for L-697,661 (sensitiza- 
tion) and decreased for the BHAPs (resistance). 
Fig. 4 shows resistance profiles for the BHAPs U-88204E and 
U-87201E. The binding affinities determined in terms of rela- 
tive ICs0's followed the same trend. Relative to the wild type, 
the IC~0 was highest for the P236L mutant and lowest for 
the P236A mutant. The preferential resistance of the 
P236 mutants to all these BHAPs was in the order 
P236A < P236R < P236H < P236T < P236L. 
It is concluded that the resistance profiles versus the P236 
HIV-1 RT mutants do not depend upon the nature of the 
BHAP used. 
Different classes of H1V-1 RT inhibitors display significant 
differences in the pattern of resistance mutations [7,14,22,3~ 
33], suggesting that they interact with different, perhaps in some 
cases overlapping, sites on the binding pocket [10]. The resis- 
tance mutations observed uring cell culture experiments with 
L-697,661 or other NNRTIs  are clustered around this binding 
pocket. The Y181C and P236L mutations require a single base 
pair change and are specifically selected in the presence of 
L-697,661 [15] and U-90152S [22], respectively. This preference 
may be based on a number of factors such as: (a) degree of 
Table 2 
Relative specific reverse transcriptase activity of HIV-1 RT and its P236 
mutants 
HIV-1 RT Specific RT activity 
(Units/mg protein) "'b 
Wild type 40,909 _+ 1148 
P236L 44,675 _+ 1676 
P236T 38,702 -+ 2036 
P236H 21,445 _+ 554 
P236R 39,373 -+ 563 
P236A 37,181 + 4236 
'*One unit is defined as 1 nmol of [3H]dTMP incorporated into 
poly(rA):oligo(dT) in 1 h at 37°C. 
~' Data represent mean + S.D. (n = 5). 
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change in susceptibility to the drug; (b) single base pair change 
as opposed to two base pair changes (e.g. Y 1811); (c) unaltered 
kinetic parameters of the resulting mutated enzyme [34]. 
One of the common characteristics of all the known NNRTIs  
is that they do not affect HIV-2 RT activity and replication. The 
replacement of Tyr ~sl with lle or Cys resulted in > 100-fold 
resistance to L-697,661 [14]. The Ile is found in the 181 position 
in HIV-2 RT and, therefore, is believed to be primarily respon- 
sible for insensitivity of HIV-2 RT towards L-697,661 [14]. 
Since the BHAPs are relatively active versus the Y 181C mutant 
[22] and select for the P236L resistance mutation [22], we 
looked into the possible role of non-conserved residues at 235, 
237, and 240 in the insensitivity of BHAPs to HIV-2 RT. We 
show here (Table 1) that HIV-2 RT resistance to U-90152S 
appears to be unrelated to the simultaneous presence of W235, 
T237, and K240 in this enzyme. Thus, the structural basis for 
the HIV-2 RT resistance to the BHAPs remains unknown. 
The exact molecular basis for resistance to NNRTIs  is largely 
unknown. Three possible related mechanisms have been pro- 
posed for resistance to NNRTIs  as a result of specific muta- 
tions in HIV-1 RT [35]. These include: lack of binding between 
the inhibitor and the mutated site, steric hinderance, and 
changes in geometry of the inhibitor-binding pocket [35]. Re- 
cent structural studies with nevirapine suggest hat most resis- 
tant mutations work by changing the geometry of the binding 
pocket that is in contact with the inhibitor [36]. It has been 
proposed that the broad spectrum of Y181C-mediated resis- 
tance may be the result of an increase in the volume of the 
hydrophobic pocket [36]. Accordingly, the Y 181C resistance to 
L-697,661 is decreased in the presence of a second mutation 
(P236L) which results in an overall decrease in pocket volume 
[36]. Consistent with this hypothesis [36], we have provided here 
biochemical data which support the view that the P236L-medi- 
ated resistance/sensitization phenomenon is the result of an 
alteration in the geometry of the inhibitor binding pocket. 
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